Relay Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Relay Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $3.89M.
- Relay Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.69M.
- Relay Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $17.00K, a 97.68% decline year-over-year.
- Relay Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $732.00K, a 670.53% increase year-over-year.
- Relay Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $524.00K, a 81.16% decline from fiscal 2024.
- Relay Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $2.78M, a 40.08% increase from fiscal 2023.
- Relay Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $1.99M, a 42.93% decline from fiscal 2022.
- Relay Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $3.48M, a 26.57% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $3.89M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.69M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $524.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | $17.00K 10-Q · filed 2025-11-06 | |
| 2024-12-31 | $2.78M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $732.00K 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $413.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $1.19M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $1.99M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $95.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $453.00K 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $1.30M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $3.48M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $1.12M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $859.00K 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $883.00K 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $4.74M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $900.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $1.12M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $2.06M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $1.22M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $442.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $367.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $351.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $613.00K 10-K · filed 2022-02-24 | |
| 2019-09-30 | $120.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $23.00K 10-Q · filed 2020-11-12 | |
| 2019-03-31 | $29.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |